ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application

Introduction: There exist controversies on recurrence and aggressiveness after use of first-line bevacizumab (BEV) which has been approved in Japan and proven to be beneficial. Therefore, we analyzed the clinical impact of BEV approval by investigating the overall clinical course and glioblastoma (G...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neurooncol Adv
Prif Awduron: Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Supplement Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699102/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.032
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg